Sargent Investment Group LLC Buys Shares of 1,449 iShares Biotechnology ETF (NASDAQ:IBB)

Sargent Investment Group LLC purchased a new position in iShares Biotechnology ETF (NASDAQ:IBB) in the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 1,449 shares of the financial services provider’s stock, valued at approximately $211,000.

Other institutional investors also recently made changes to their positions in the company. Highline Wealth Partners LLC bought a new position in iShares Biotechnology ETF during the third quarter valued at about $30,000. Bbjs Financial Advisors LLC acquired a new stake in iShares Biotechnology ETF in the 2nd quarter valued at about $31,000. Ashton Thomas Securities LLC bought a new position in shares of iShares Biotechnology ETF during the 3rd quarter valued at about $36,000. Voisard Asset Management Group Inc. acquired a new position in shares of iShares Biotechnology ETF in the 3rd quarter worth approximately $59,000. Finally, Aptus Capital Advisors LLC raised its holdings in shares of iShares Biotechnology ETF by 36.5% in the 3rd quarter. Aptus Capital Advisors LLC now owns 426 shares of the financial services provider’s stock worth $62,000 after purchasing an additional 114 shares in the last quarter. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Price Performance

IBB stock opened at $140.09 on Friday. iShares Biotechnology ETF has a 12 month low of $116.70 and a 12 month high of $150.57. The firm has a 50 day simple moving average of $144.68 and a 200 day simple moving average of $141.56.

iShares Biotechnology ETF Announces Dividend

The business also recently disclosed a dividend, which was paid on Monday, September 30th. Stockholders of record on Wednesday, September 25th were given a dividend of $0.2005 per share. The ex-dividend date of this dividend was Wednesday, September 25th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.